HC Wainwright & Co. Maintains Buy on Revance Therapeutics, Lowers Price Target to $41
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao maintains a 'Buy' rating on Revance Therapeutics (NASDAQ:RVNC) but lowers the price target from $48 to $41.

August 09, 2023 | 10:12 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Revance Therapeutics' price target has been lowered from $48 to $41 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target by HC Wainwright & Co. could potentially create a negative sentiment among investors, which might put downward pressure on the stock price in the short term. However, the maintenance of the 'Buy' rating indicates that the analyst still sees potential in the company, which could offset the negative impact of the lowered price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100